Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: | Egoderm |
Active Ingredients: | Ichthammol 1%w/w Zinc oxide 15%w/w |
Dosage Form: | Topical ointment |
New Zealand Sponsor: | Douglas Pharmaceuticals Limited |
Manufacturer: | Ego Pharmaceuticals Pty Limited, Melbourne, Australia |
Product: | Glypressin |
Active Ingredient: | Terlipressin acetate 1mg equivalent to terlipressin 0.85mg |
Dosage Form: | Solution for injection |
New Zealand Sponsor: | Pharmaco (NZ) Limited |
Manufacturers: | Zentiva AS (Czech Republic), Prague, Czech Republic Ferring Pharmaceuticals China (Co) Limited, Zhongshan City, China |
Product: | Keytruda |
Active Ingredient: | Pembrolizumab 25mg/mL |
Dosage Form: | Concentrate for infusion |
New Zealand Sponsor: | Merck Sharp & Dohme (New Zealand) Limited |
Manufacturers: | MSD International GmbH (Singapore Branch), Singapore City, Singapore MSD International GmbH, t/a MSD Ireland (Carlow), Carlow, Ireland |
Product: | Tagrisso |
Active Ingredient: | Osimertinib mesilate 47.7mg equivalent to osimertinib 40mg |
Dosage Form: | Film coated tablet |
New Zealand Sponsor: | AstraZeneca Limited |
Manufacturer: | AstraZeneca AB, Sodertalje, Sweden |
Product: | Tagrisso |
Active Ingredient: | Osimertinib mesilate 95.4mg equivalent to osimertinib 80mg |
Dosage Form: | Film coated tablet |
New Zealand Sponsor: | AstraZeneca Limited |
Manufacturer: | AstraZeneca AB, Sodertalje, Sweden |
Dated this 16th day of April 2024.
DEREK FITZGERALD, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).